To further validate the network pharmacology prediction of naringin in RA-FLS, we performed Western blot to measure the phosphorylation level of Akt and ERK, and the result indicated that naringin also inhibits the expression level of p-Akt and p-ERK (p < 0.05) in a dose-dependent manner (Figure 9C). The gene discussed is MAPK1; the disease is rheumatoid arthritis.